Israel Englander Halozyme Therapeutics, Inc. Transaction History

Millennium Management LLC

$192 Billion
Q4 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 95,424 shares of HALO stock, worth $5.68 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

95,424

Previous 26,919 254.49%

Holding current value

$5.68 Million

Previous $1.54 Million 196.23%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$42.57 - $61.09 $2.92 Million - $4.18 Million	68,505 Added 254.49%	95,424 $4.56 Million
Q3 2024 Nov 14, 2024	SELL	$51.3 - $64.42 $20.3 Million - $25.5 Million	-396,271 Reduced 93.64%	26,919 $1.54 Million
Q2 2024 Aug 14, 2024	BUY	$37.81 - $52.4 $11 Million - $15.3 Million	291,122 Added 220.43%	423,190 $22.2 Million
Q1 2024 May 15, 2024	SELL	$33.68 - $41.95 $6.02 Million - $7.5 Million	-178,838 Reduced 57.52%	132,068 $5.37 Million
Q4 2023 Feb 14, 2024	SELL	$33.32 - $42.1 $49.9 Million - $63.1 Million	-1,498,903 Reduced 82.82%	310,906 $11.5 Million
Q2 2023 Aug 14, 2023	BUY	$30.28 - $38.74 $24 Million - $30.6 Million	791,020 Added 77.64%	1,809,809 $65.3 Million
Q1 2023 May 15, 2023	BUY	$32.86 - $55.7 $31.8 Million - $53.9 Million	967,665 Added 1892.78%	1,018,789 $38.9 Million
Q4 2022 Feb 14, 2023	SELL	$40.06 - $59.44 $36.9 Million - $54.8 Million	-921,614 Reduced 94.74%	51,124 $2.91 Million
Q3 2022 Nov 14, 2022	BUY	$38.53 - $51.78 $34.9 Million - $46.9 Million	905,754 Added 1352.19%	972,738 $38.5 Million
Q2 2022 Aug 15, 2022	BUY	$37.35 - $48.3 $139,913 - $180,931	3,746 Added 5.92%	66,984 $2.95 Million
Q1 2022 May 16, 2022	SELL	$31.97 - $41.06 $3.1 Million - $3.98 Million	-96,860 Reduced 60.5%	63,238 $2.52 Million
Q4 2021 Feb 14, 2022	SELL	$31.82 - $40.75 $3.35 Million - $4.29 Million	-105,175 Reduced 39.65%	160,098 $6.44 Million
Q3 2021 Nov 15, 2021	BUY	$38.47 - $46.42 $1.91 Million - $2.3 Million	49,650 Added 23.03%	265,273 $10.8 Million
Q2 2021 Aug 16, 2021	BUY	$38.84 - $51.31 $7.14 Million - $9.43 Million	183,797 Added 577.51%	215,623 $9.79 Million
Q1 2021 May 17, 2021	SELL	$39.51 - $51.45 $11.3 Million - $14.7 Million	-285,349 Reduced 89.97%	31,826 $1.33 Million
Q4 2020 Feb 16, 2021	BUY	$25.81 - $43.62 $8.19 Million - $13.8 Million	317,175 New	317,175 $13.5 Million
Q3 2020 Nov 16, 2020	SELL	$25.74 - $29.63 $1.1 Million - $1.26 Million	-42,658 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$16.25 - $26.81 $6.53 Million - $10.8 Million	-402,044 Reduced 90.41%	42,658 $1.14 Million
Q1 2020 May 14, 2020	SELL	$13.9 - $21.83 $8.48 Million - $13.3 Million	-610,261 Reduced 57.85%	444,702 $8 Million
Q4 2019 Feb 14, 2020	BUY	$14.93 - $19.53 $11 Million - $14.4 Million	739,802 Added 234.74%	1,054,963 $18.7 Million
Q3 2019 Nov 14, 2019	BUY	$15.2 - $17.69 $4.79 Million - $5.58 Million	315,161 New	315,161 $4.89 Million
Q4 2018 Feb 14, 2019	SELL	$13.33 - $18.66 $986,366 - $1.38 Million	-73,996 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$16.68 - $18.41 $145,416 - $160,498	-8,718 Reduced 10.54%	73,996 $1.35 Million
Q2 2018 Aug 14, 2018	SELL	$16.87 - $20.3 $21.8 Million - $26.2 Million	-1,290,533 Reduced 93.98%	82,714 $1.4 Million
Q1 2018 May 15, 2018	SELL	$17.06 - $21.2 $1.74 Million - $2.16 Million	-101,896 Reduced 6.91%	1,373,247 $26.9 Million
Q4 2017 Feb 14, 2018	BUY	$16.75 - $20.8 $12.3 Million - $15.3 Million	733,706 Added 98.96%	1,475,143 $29.9 Million
Q3 2017 Nov 14, 2017	BUY	$11.76 - $17.4 $8.72 Million - $12.9 Million	741,437	741,437 $12.9 Million

Others Institutions Holding HALO

# of Institutions

550

Shares Held

124M

Call Options Held

668K

Put Options Held

259K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $8.29B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account